IM Cannabis Corp. (NASDAQ:IMCC) Sees Significant Decrease in Short Interest

Posted by George Bondi on Jul 29th, 2026

IM Cannabis Corp. (NASDAQ:IMCC – Get Free Report) was the target of a significant drop in short interest in July. As of July 15th, there was short interest totaling 214,028 shares, a drop of 42.7% from the June 30th total of 373,494 shares. Approximately 3.7% of the company’s stock are sold short. Based on an average trading volume of 381,600 shares, the short-interest ratio is presently 0.6 days.

IM Cannabis Price Performance

Shares of IMCC stock traded down $0.00 during trading hours on Wednesday, reaching $0.10. 335,025 shares of the stock were exchanged, compared to its average volume of 2,488,211. The business’s fifty day moving average is $0.20 and its two-hundred day moving average is $0.55. The firm has a market capitalization of $646,880.00, a P/E ratio of -0.06 and a beta of 2.04. IM Cannabis has a 12-month low of $0.10 and a 12-month high of $3.13.

Institutional Investors Weigh In On IM Cannabis

An institutional investor recently bought a new stake in IM Cannabis stock. DRW Securities LLC acquired a new position in shares of IM Cannabis Corp. (NASDAQ:IMCC – Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 23,060 shares of the company’s stock, valued at approximately $32,000. DRW Securities LLC owned about 0.39% of IM Cannabis at the end of the most recent quarter. 7.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of IM Cannabis in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, IM Cannabis presently has a consensus rating of “Sell”.

Read Our Latest Analysis on IMCC

IM Cannabis Company Profile

(Get Free Report)

IM Cannabis Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.

The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards.